Effect of triiodothyronine on bronchial asthma. II.
Triiodothyronine (T3) administration to patients suffering from chronic bronchial asthma or patients suffering from nasopharyngeal allergy was reported to ameliorate the attacks. Twelve patients aged less than 35 years suffering from chronic bronchial asthma for more than 5 years, who were maintained on usual anti-asthmatic drugs with the exception of steroids and chromoglycate and who were not the subject of repeated attacks of bronchitis were chosen for the study. Each patient was given T3 orally as 40 micron/day divided into two doses, for a period of 60 days. The drug increased the peak flow in all cases. The increase averaged 24.6% +/- 8.48 (P less than 0.001). Three cases reported marked improvement and four were able to reduce the dose of anti-asthmatic drugs. There was no significant change in the pulse rate, ECG, body weight, blood pressure, or appetite. One patient complained of insomnia and another of increased anxiety. It is possible that T3 exerts its beneficial effect through correcting the level of C-AMP, which is known to be low in asthmatics, through improvement of body mechanism for antibody formation, or through other unidentified mechanisms.
D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010366:Peak Expiratory Flow Rate; D014284:Triiodothyronine / Q000009:adverse effects / Q000627:therapeutic use*
D014284:Triiodothyronine; D004837:Epinephrine